Total Payments
$226,385
2024 Payments
$8,778
Companies
95
Transactions
1,518
Medicare Patients
8,465
Medicare Billing
$2.0M
Payment Breakdown by Category
Consulting$142,344 (62.9%)
Other$37,504 (16.6%)
Food & Beverage$31,100 (13.7%)
Travel$15,043 (6.6%)
Education$393.52 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $142,344 | 63 | 62.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $35,008 | 23 | 15.5% |
| Food and Beverage | $31,100 | 1,352 | 13.7% |
| Travel and Lodging | $15,043 | 59 | 6.6% |
| Honoraria | $2,497 | 3 | 1.1% |
| Education | $393.52 | 18 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $37,349 | 86 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $25,528 | 90 | $0 (2024) |
| Seagen Inc. | $19,360 | 39 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $19,196 | 143 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $17,391 | 128 | $0 (2024) |
| ADC Therapeutics America, Inc. | $17,190 | 16 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $11,665 | 10 | $0 (2017) |
| Bayer Healthcare Pharmaceuticals Inc. | $11,503 | 46 | $0 (2024) |
| PFIZER INC. | $10,861 | 119 | $0 (2024) |
| Exelixis Inc. | $9,608 | 41 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,778 | 231 | AstraZeneca Pharmaceuticals LP ($2,532) |
| 2023 | $40,029 | 239 | Seagen Inc. ($19,126) |
| 2022 | $17,270 | 233 | ADC Therapeutics America, Inc. ($8,536) |
| 2021 | $17,689 | 121 | Lilly USA, LLC ($4,845) |
| 2020 | $34,031 | 77 | Lilly USA, LLC ($10,331) |
| 2019 | $60,406 | 244 | Lilly USA, LLC ($21,621) |
| 2018 | $20,334 | 190 | E.R. Squibb & Sons, L.L.C. ($11,363) |
| 2017 | $27,848 | 183 | Millennium Pharmaceuticals, Inc. ($11,665) |
All Payment Transactions
1,518 individual payment records from CMS Open Payments — Page 1 of 61
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.84 | General |
| Category: Hematology/Oncology | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $9.48 | General |
| Category: Oncology | ||||||
| 12/17/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.94 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $25.46 | General |
| 12/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.90 | General |
| Category: Oncology | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $6.89 | General |
| Category: Hematology | ||||||
| 12/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $27.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $22.95 | General |
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $32.09 | General |
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,005.00 | General |
| 12/02/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $17.48 | General |
| Category: Hematology/Oncology | ||||||
| 11/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $25.04 | General |
| 11/26/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $32.62 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $28.53 | General |
| Category: Oncology | ||||||
| 11/26/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $31.67 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,005.00 | General |
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $19.92 | General |
| 11/21/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 37 | 2,088 | 31,003 | $1.9M | $432,848 |
| 2022 | 33 | 1,850 | 36,448 | $1.4M | $341,124 |
| 2021 | 29 | 1,667 | 40,183 | $1.7M | $535,537 |
| 2020 | 46 | 2,860 | 65,311 | $3.6M | $732,892 |
Total Patients
8,465
Total Services
172,945
Medicare Billing
$2.0M
Procedure Codes
145
All Medicare Procedures & Services
145 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 28 | 7,320 | $468,093 | $133,019 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 245 | 514 | $199,767 | $47,748 | 23.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 373 | 647 | $178,850 | $40,131 | 22.4% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 14 | 432 | $282,528 | $39,947 | 14.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 55 | 378 | $158,256 | $36,830 | 23.3% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 16 | 1,800 | $133,200 | $29,084 | 21.8% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 21 | 11,180 | $67,080 | $15,345 | 22.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 43 | 501 | $51,323 | $10,852 | 21.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 485 | 1,405 | $40,457 | $10,663 | 26.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 52 | 52 | $34,939 | $8,373 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 68 | $37,320 | $8,301 | 22.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 28 | 166 | $33,920 | $7,924 | 23.4% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 26 | 93 | $19,530 | $6,703 | 34.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 37 | 44 | $26,180 | $5,614 | 21.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $16,769 | $4,091 | 24.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 30 | 87 | $18,006 | $4,064 | 22.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 63 | 350 | $22,750 | $3,696 | 16.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 32 | $9,856 | $2,941 | 29.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 23 | $9,257 | $2,310 | 25.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 21 | 93 | $14,316 | $2,011 | 14.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 31 | $6,624 | $1,879 | 28.4% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 17 | 38 | $6,840 | $1,647 | 24.1% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 22 | 107 | $6,732 | $1,630 | 24.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 34 | 119 | $6,809 | $1,409 | 20.7% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 24 | 1,580 | $61,351 | $1,315 | 2.1% |
About Dr. Mazen Khattab, MD
Dr. Mazen Khattab, MD is a Medical Oncology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205804283.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mazen Khattab, MD has received a total of $226,385 in payments from pharmaceutical and medical device companies, with $8,778 received in 2024. These payments were reported across 1,518 transactions from 95 companies. The most common payment nature is "Consulting Fee" ($142,344).
As a Medicare-enrolled provider, Khattab has provided services to 8,465 Medicare beneficiaries, totaling 172,945 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 145 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Phoenix, AZ
- Active Since 03/08/2006
- Last Updated 09/11/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1205804283
Products in Payments
- VERZENIO (Drug) $30,317
- TUKYSA (Drug) $19,104
- OPDIVO (Biological) $12,908
- TASIGNA (Drug) $9,028
- Cabometyx (Drug) $8,917
- TAGRISSO (Drug) $6,415
- Xofigo (Drug) $6,272
- NINLARO (Drug) $6,143
- ALUNBRIG (Drug) $5,708
- KISQALI (Drug) $5,707
- CALQUENCE (Drug) $4,474
- LORBRENA (Drug) $4,237
- EMPLICITI (Biological) $3,764
- SUTENT (Drug) $3,217
- CYRAMZA (Drug) $2,948
- XPOVIO (Drug) $2,749
- TECENTRIQ (Biological) $2,740
- Vitrakvi (Drug) $2,575
- LYNPARZA (Drug) $2,193
- Enhertu (Drug) $2,071
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Phoenix
Dr. Jason Salganick, Md, MD
Medical Oncology — Payments: $1.9M
Medical Oncology $1.9M
Panayiotis Savvides, Md, MD
Medical Oncology — Payments: $217,105
Medical Oncology $217,105
Amber Flaherty, M.d, M.D
Medical Oncology — Payments: $41,476
Medical Oncology $41,476
Tania Cortas, Md, MD
Medical Oncology — Payments: $36,718
Medical Oncology $36,718
Waqas Arslan, M.d, M.D
Medical Oncology — Payments: $34,523
Medical Oncology $34,523
Dr. Amir Azadi, M.d, M.D
Medical Oncology — Payments: $23,762
Medical Oncology $23,762